View in EDS HTML Full Text PDF Full Text

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Saved in:
Bibliographic Details
Title: Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
Authors: Jimenez-Vicente C; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain., Cardus A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Castaño-Diez S; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Hemopathology Unit, Pathology Department. Hospital Clinic de Barcelona, Barcelona, Spain., Ramil G; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain., Garcia-Avila S; Hematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research Institute, Barcelona, Spain., Gomez-Perez L; Hematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research Institute, Barcelona, Spain., Esteban D; Hematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de Barcelona, Barcelona, Spain., Arribas I; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain., Sturla AL; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain., Lopez-Guerra M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Hemopathology Unit, Pathology Department. Hospital Clinic de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Martinez-Roca A; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Cortes-Bullich A; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Perez-Valencia AI; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Zugasti I; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain., Monge I; Pharmacy Department, Hospital Clínic de Barcelona, Barcelona, Spain., Carcelero E; Pharmacy Department, Hospital Clínic de Barcelona, Barcelona, Spain., Vall-Llovera F; Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain., Vives S; Hematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de Barcelona, Barcelona, Spain., Sierra J; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain., Nomdedeu J; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain., Oñate G; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain., Garrido A; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain., Pratcorona M; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain., Pomares H; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain., Arnan M; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain., Guijarro F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Hemopathology Unit, Pathology Department. Hospital Clinic de Barcelona, Barcelona, Spain., Diaz-Beya M; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Josep Carreras Leukemia Research Institute, Barcelona, Spain., Esteve J; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain. jesteve@clinic.cat.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. jesteve@clinic.cat.; University of Barcelona, Barcelona, Spain. jesteve@clinic.cat.; Josep Carreras Leukemia Research Institute, Barcelona, Spain. jesteve@clinic.cat.
Corporate Authors: Spanish CETLAM Group
Source: Blood cancer journal [Blood Cancer J] 2025 May 14; Vol. 15 (1), pp. 94. Date of Electronic Publication: 2025 May 14.
Publication Type: Letter
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40368916
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jimenez-Vicente+C%22">Jimenez-Vicente C</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cardus+A%22">Cardus A</searchLink>; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Castaño-Diez+S%22">Castaño-Diez S</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Hemopathology Unit, Pathology Department. Hospital Clinic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Ramil+G%22">Ramil G</searchLink>; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Garcia-Avila+S%22">Garcia-Avila S</searchLink>; Hematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research Institute, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Gomez-Perez+L%22">Gomez-Perez L</searchLink>; Hematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research Institute, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Esteban+D%22">Esteban D</searchLink>; Hematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Arribas+I%22">Arribas I</searchLink>; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sturla+AL%22">Sturla AL</searchLink>; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lopez-Guerra+M%22">Lopez-Guerra M</searchLink>; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Hemopathology Unit, Pathology Department. Hospital Clinic de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Martinez-Roca+A%22">Martinez-Roca A</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cortes-Bullich+A%22">Cortes-Bullich A</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Perez-Valencia+AI%22">Perez-Valencia AI</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Zugasti+I%22">Zugasti I</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Monge+I%22">Monge I</searchLink>; Pharmacy Department, Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Carcelero+E%22">Carcelero E</searchLink>; Pharmacy Department, Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Vall-Llovera+F%22">Vall-Llovera F</searchLink>; Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Vives+S%22">Vives S</searchLink>; Hematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sierra+J%22">Sierra J</searchLink>; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Nomdedeu+J%22">Nomdedeu J</searchLink>; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Oñate+G%22">Oñate G</searchLink>; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Garrido+A%22">Garrido A</searchLink>; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Pratcorona+M%22">Pratcorona M</searchLink>; Hematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Pomares+H%22">Pomares H</searchLink>; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Arnan+M%22">Arnan M</searchLink>; Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Guijarro+F%22">Guijarro F</searchLink>; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Hemopathology Unit, Pathology Department. Hospital Clinic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Diaz-Beya+M%22">Diaz-Beya M</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Josep Carreras Leukemia Research Institute, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Esteve+J%22">Esteve J</searchLink>; Hematology Department. Hospital Clínic de Barcelona, Barcelona, Spain. jesteve@clinic.cat.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. jesteve@clinic.cat.; University of Barcelona, Barcelona, Spain. jesteve@clinic.cat.; Josep Carreras Leukemia Research Institute, Barcelona, Spain. jesteve@clinic.cat.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Spanish+CETLAM+Group%22">Spanish CETLAM Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2025 May 14; Vol. 15 (1), pp. 94. <i>Date of Electronic Publication: </i>2025 May 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40368916
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-025-01298-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 94
    Titles:
      – TitleFull: Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jimenez-Vicente C
      – PersonEntity:
          Name:
            NameFull: Cardus A
      – PersonEntity:
          Name:
            NameFull: Castaño-Diez S
      – PersonEntity:
          Name:
            NameFull: Ramil G
      – PersonEntity:
          Name:
            NameFull: Garcia-Avila S
      – PersonEntity:
          Name:
            NameFull: Gomez-Perez L
      – PersonEntity:
          Name:
            NameFull: Esteban D
      – PersonEntity:
          Name:
            NameFull: Arribas I
      – PersonEntity:
          Name:
            NameFull: Sturla AL
      – PersonEntity:
          Name:
            NameFull: Lopez-Guerra M
      – PersonEntity:
          Name:
            NameFull: Martinez-Roca A
      – PersonEntity:
          Name:
            NameFull: Cortes-Bullich A
      – PersonEntity:
          Name:
            NameFull: Perez-Valencia AI
      – PersonEntity:
          Name:
            NameFull: Zugasti I
      – PersonEntity:
          Name:
            NameFull: Monge I
      – PersonEntity:
          Name:
            NameFull: Carcelero E
      – PersonEntity:
          Name:
            NameFull: Vall-Llovera F
      – PersonEntity:
          Name:
            NameFull: Vives S
      – PersonEntity:
          Name:
            NameFull: Sierra J
      – PersonEntity:
          Name:
            NameFull: Nomdedeu J
      – PersonEntity:
          Name:
            NameFull: Oñate G
      – PersonEntity:
          Name:
            NameFull: Garrido A
      – PersonEntity:
          Name:
            NameFull: Pratcorona M
      – PersonEntity:
          Name:
            NameFull: Pomares H
      – PersonEntity:
          Name:
            NameFull: Arnan M
      – PersonEntity:
          Name:
            NameFull: Guijarro F
      – PersonEntity:
          Name:
            NameFull: Diaz-Beya M
      – PersonEntity:
          Name:
            NameFull: Esteve J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 05
              Text: 2025 May 14
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1